Gravier Pierre 4

What Happened
Pierre Gravier, Chief Financial Officer of PTC Therapeutics (PTCT), disposed of 3,494 shares on July 14, 2026 at $80.35 per share, generating proceeds of approximately $280,743. The sale was made pursuant to an irrevocable sell-to-cover election to satisfy tax withholding upon the vesting of restricted stock units (RSUs).

Key Details

• Transaction date and price: July 14, 2026 — 3,494 shares sold at $80.35 each.
• Total proceeds: ~ $280,743.
• Reason / footnote: The sale was an automatic sell-to-cover to satisfy withholding obligations related to the vesting of 6,500 RSUs from a July 13, 2023 grant (footnote F1).
• Additional disclosure: Filing notes inclusion of 162 shares acquired under the issuer’s employee stock purchase plan for the period ended June 30, 2026 (footnote F2).
• Shares owned after transaction: Not specified in the Form 4 filing.
• Filing timeliness: Report filed July 16, 2026 (within the SEC’s typical two-business-day Form 4 reporting window).

Context
Sell-to-cover transactions are routine tax-related disposals triggered when RSUs vest and do not necessarily indicate the insider’s view of the company. This was a sale to meet withholding obligations rather than an open-market sell motivated by diversification or liquidity needs (the filing does not state motivation).